Advances of Targeted Therapy for Acute Myeloid Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2023.04.051
- Author:
Xiao-Ling WEN
1
;
Ruo-Qi LI
2
;
Lin-Hua YANG
2
;
Rui-Juan ZHANG
3
Author Information
1. Department of Hematology, The First People's Hospitalof Yibin, Yibin 644000, Sichuan Province, China.
2. Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
3. Department of Hematology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, Shanxi Province, China.E-mail: 13593169668@163.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
chimeric antigen receptor T cell;
targeted therapy;
antibody-drug conjugate
- MeSH:
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Immunotherapy;
Immunotherapy, Adoptive;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(4):1252-1256
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia (AML) has highly heterogeneous clinical manifestations and poor prognosis, and traditional chemotherapy is the main treatment. In recent years, with the in-depth development of next-generation sequencing technology, the treatment of AML is gradually exploring the precise targeted therapy in the direction of molecular biology and immunophenotype. The advent of various small-molecule inhibitors and immune-targeted drugs has brought hope to patients who cannot tolerate intensive chemotherapy or with relapsed/refractory AML. Compared with traditional chemotherapy, targeted therapy has the advantages of significant curative effect and fewer adverse effects. This article reviews the latest research progress of targeted drug therapy for AML.
